Bioventix (GB:BVXP) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Bioventix PLC reported a 6% increase in revenue to £13.6 million and a 5% rise in profit before tax to £10.6 million for the fiscal year ending June 2024. The company’s significant revenue is derived from their high-affinity monoclonal antibodies used in clinical diagnostics, seeing particular growth in the vitamin D and thyroid function sectors. While facing challenges in troponin royalties, Bioventix is optimistic about new applications in cardiac risk assessment and continued growth in the Chinese market.
For further insights into GB:BVXP stock, check out TipRanks’ Stock Analysis page.